- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07713056
Clinical Characteristics of Pigmentary Glaucoma and Efficacy Analysis of Ab-interno 120° Trabeculotomy
17. juli 2026 oppdatert av: Zhongnan Hospital
Clinical Characteristics of Pigmentary Glaucoma and Efficacy Analysis of Ab-interno 120° Trabeculotomy: A Case Series Study
This study aims to investigate the clinical characteristics of pigmentary glaucoma and evaluate the efficacy and safety of ab-interno 120° trabeculotomy during the 6-month postoperative follow-up period.
Studieoversikt
Status
Rekruttering
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This is a single-center, retrospective case series study.
Patients with pigmentary glaucoma treated at Zhongnan Hospital of Wuhan University will be enrolled.
By systematically collecting their baseline demographic characteristics, ocular examination results, and prior treatment history, the study aims to summarize the distribution pattern of clinical features of pigmentary glaucoma.
With the 6-month postoperative follow-up as the primary endpoint, the study will evaluate the intraocular pressure-lowering effect of ab-interno 120° trabeculotomy, changes in medication dependence, and the stability of visual field and retinal nerve fiber layer, while observing the occurrence of related intraoperative and postoperative complications, so as to provide clinical evidence for individualized surgical treatment of pigmentary glaucoma.
Studietype
Observasjonsmessig
Registrering (Antatt)
11
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Min Ke, doctor
- Telefonnummer: 18672395959
- E-post: Keminyk@163.com
Studer Kontakt Backup
- Navn: Xiaomin Chen, doctor
- Telefonnummer: 13657237773
- E-post: xminchen@whu.edu.cn
Studiesteder
-
-
Hubei
-
Wuhan, Hubei, Kina, 430071
- Rekruttering
- Zhongnan Hospital of Wuhan University
-
Ta kontakt med:
- Min Ke, Doctor
- Telefonnummer: +86-18672395959
- E-post: keminyk@163.com
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
This study included patients with pigmentary glaucoma who underwent primary isolated ab-interno 120° trabeculotomy at Zhongnan Hospital of Wuhan University.
All patients had complete baseline data (including intraocular pressure, visual field, and OCT retinal nerve fiber layer measurements) and at least 6 months of follow-up data.
Patients with other types of glaucoma, prior ocular trauma or surgery history, combined intraoperative procedures, severe systemic diseases, or incomplete key data were excluded.
Beskrivelse
Inclusion Criteria:
- Meet the clinical diagnostic criteria for pigmentary glaucoma, with typical signs of pigment dispersion syndrome, extensive trabecular meshwork pigmentation, pathological intraocular pressure elevation, glaucomatous optic nerve damage, and characteristic visual field defects;
- Underwent primary isolated ab-interno 120° trabeculotomy as the initial surgical treatment;
- Have complete preoperative and postoperative examination data, including slit-lamp biomicroscopy, gonioscopy, intraocular pressure, visual field, and OCT RNFL measurements;
- Able to complete regular follow-up for at least 6 months postoperatively.
Exclusion Criteria:
- Patients with exfoliation syndrome, exfoliative glaucoma, or other types of primary or secondary glaucoma;
- Patients with a history of ocular trauma, intraocular surgery, uveitis, severe retinopathy, or other ocular diseases affecting intraocular pressure and visual function assessment;
- Patients who underwent combined procedures such as concurrent cataract surgery or other anti-glaucoma surgeries during the operation;
- Patients with severe systemic diseases, cognitive or psychiatric disorders that prevent cooperation with examinations and follow-up;
- Patients with missing key clinical or follow-up data that preclude efficacy and prognosis evaluation.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Intraocular Pressure (IOP) at 6 Months Postoperatively
Tidsramme: 6 months postoperatively
|
Change in intraocular pressure from baseline to 6 months after ab-interno 120° trabeculotomy, including the mean IOP level, absolute reduction, and percentage reduction relative to baseline.
|
6 months postoperatively
|
|
Change in the Number of Intraocular Pressure-Lowering Medications at 6 Months
Tidsramme: 6 months postoperatively
|
Change in the number of glaucoma medications used by patients, comparing baseline to 6 months after surgery.
|
6 months postoperatively
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Changes in Visual Field Parameters at 6 Months Postoperatively
Tidsramme: 6 months postoperatively
|
Changes in visual field mean deviation (MD) from baseline to 6 months postoperatively.
|
6 months postoperatively
|
|
Changes in Visual Field Parameters at 6 Months Postoperatively
Tidsramme: 6 months postoperatively
|
Changes in pattern standard deviation (PSD) from baseline to 6 months postoperatively.
|
6 months postoperatively
|
|
Changes in Visual Acuity at 6 Months Postoperatively
Tidsramme: 6 months postoperatively
|
Changes in best-corrected visual acuity (BCVA) from baseline to 6 months postoperatively.
|
6 months postoperatively
|
|
Status of Trabeculotomy Site on Gonioscopy
Tidsramme: 6 months postoperatively
|
Patency and morphological status of the trabecular meshwork incision site as assessed by gonioscopy at 6 months postoperatively.
|
6 months postoperatively
|
|
Improvement in Pupillary Block and Iris Configuration
Tidsramme: 6 months postoperatively
|
Improvement in pupillary block and iris configuration as assessed by anterior segment optical coherence tomography (OCT) at 6 months postoperatively.
|
6 months postoperatively
|
|
Rate of Secondary Glaucoma Surgery
Tidsramme: From the day of surgery to 6 months postoperatively
|
Proportion of patients who require additional glaucoma surgery during the 6-month follow-up period.
|
From the day of surgery to 6 months postoperatively
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Hovedetterforsker: Wen Zeng, doctor, Zhongnan Hospital
- Hovedetterforsker: Nan Zhang, doctor, Zhongnan Hospital
- Hovedetterforsker: Xuetian Yu, The Second Clinical College of Wuhan University
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
1. april 2026
Primær fullføring (Antatt)
30. september 2026
Studiet fullført (Antatt)
30. september 2026
Datoer for studieregistrering
Først innsendt
13. juli 2026
Først innsendt som oppfylte QC-kriteriene
17. juli 2026
Først lagt ut (Faktiske)
20. juli 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
20. juli 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
17. juli 2026
Sist bekreftet
1. juli 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 20260523
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
UBESLUTTE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .